Pemetrexed - Eagle Pharmaceuticals

Drug Profile

Pemetrexed - Eagle Pharmaceuticals

Alternative Names: EP-5101; Pemetrexed RTD; RTD Pemetrexed Injection

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eagle Pharmaceuticals
  • Class Antineoplastics; Benzamides; Glutamates; Hypoxanthines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Mesothelioma; Non-small cell lung cancer

Most Recent Events

  • 27 Oct 2017 FDA issues tentative approval to pemetrexed injection 25 mg/mL for Non-small cell lung cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater, Monotherapy), Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater), Non-small cell lung cancer (Combination therapy; Metastatic disease; Late-stage disease) and Mesothelioma (Combination therapy; Inoperable/Unresectable)
  • 28 Feb 2017 FDA assigns PDUFA action date of 30/10/2017 for Pemetrexed for Mesothelioma and Non-small cell lung cancer
  • 31 Dec 2016 Preregistration for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top